Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $73.4 million.

  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) rose 13.57% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 13.57%. This contributed to the annual value of $63.2 million for FY2024, which is 23.18% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $73.4 million, which was up 1.28% from $72.5 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $73.4 million for Q3 2025, and its period low was $38.0 million during Q1 2022.
  • Over the past 3 years, Phathom Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $58.6 million (recorded in 2024), while the average stood at $60.1 million.
  • Data for Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY soared of 46.27% (in 2023) over the last 5 years.
  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $39.1 million in 2022, then surged by 31.11% to $51.3 million in 2023, then climbed by 23.18% to $63.2 million in 2024, then increased by 13.57% to $73.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $73.4 million in Q3 2025, compared to $72.5 million in Q2 2025 and $72.0 million in Q1 2025.